Up‐regulation of the Kv3.4 potassium channel subunit in early stages of Alzheimer's disease
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Gene expression throughout the different stages of Alzheimer's disease was analysed in samples from cerebral cortex. The gene encoding the voltage‐gated potassium channel Kv3.4 was already overexpressed in early stages of the disease, and in advanced stages Kv3.4 was present at high levels in neurodegenerative structures. This subunit regulates delayed‐rectifier currents, which are primary determinants of spike repolarization in neurones. In unique samples from a patient with Alzheimer's disease whose amount of amyloid plaques was decreased by β amyloid immunization, Kv3.4 was overexpressed. The channel subunit was expressed in the neuropil, in the remaining conventional plaques in the frontal cortex and in collapsed plaques in the orbitary cortex. Therefore, amyloid deposition in plaques does not seem to be responsible for the increase in Kv3.4 levels. Nevertheless, Kv3.4 up‐regulation is related to amyloid pathology, given that transgenic mice with the Swedish mutation of amyloid precursor protein showed increased expression of Kv3.4. Up‐regulation of voltage‐gated potassium channel subunits alters potassium currents in neurones and leads to altered synaptic activity that may underlie the neurodegeneration observed in Alzheimer's disease. Thus, Kv3.4 likely represents a novel therapeutic target for the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530 · cited 1×
“Additional support for the concept that soluble Ab is involved in neuronal injury comes from human neuropathological studies reporting that the clinical severity of AD correlates quantitatively better with soluble Ab levels than with plaque load in the brain (Lue et al. 1999; Gouras et al. 2000).”
BackgroundNeuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397
Molecular Diversity of K+ Channels
COETZEE, W. A., AMARILLO, Y., CHIU, J., CHOW, A., LAU, D., McCORMACK, T., MORENA, H., NADAL, M. S., OZAITA, A., POUNTNEY, D., et al. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb11293.x · Cited by 1,095
Intraneuronal Aβ42 Accumulation in Human Brain
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991
Kv3 channels: voltage-gated K+ channels designed for high-frequency repetitive firing
Rudy, B., & McBain, C. J. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01892-0 · Cited by 781
IRIZARRY, M. C., MCNAMARA, M., FEDORCHAK, K., HSIAO, K., & HYMAN, B. T. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199709000-00002 · Cited by 649
SZE, C.-I., TRONCOSO, J. C., KAWAS, C., MOUTION, P., PRICE, D. L., & MARTIN, L. J. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199708000-00011 · Cited by 562
Abbott, G. W., Butler, M. H., Bendahhou, S., Dalakas, M. C., Ptacek, L. J., & Goldstein, S. A. N. (2001) · Cell · doi:10.1016/s0092-8674(01)00207-0 · Cited by 294
Takashima, A., Honda, T., Yasutake, K., Michel, G., Murayama, O., Murayama, M., Ishiguro, K., & Yamaguchi, H. (1998) · Neuroscience Research · doi:10.1016/s0168-0102(98)00061-3 · Cited by 287
Cited by
Voltage-gated potassium channels as therapeutic targets
Wulff, H., Castle, N. A., & Pardo, L. A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2983 · Cited by 799
Natural products as a source of Alzheimer's drug leads
Williams, P., Sorribas, A., & Howes, M.-J. R. (2011) · Nat. Prod. Rep. · doi:10.1039/c0np00027b · Cited by 404
Salminen, A., Ojala, J., Kauppinen, A., Kaarniranta, K., & Suuronen, T. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.01.001 · Cited by 346
Waters, M. F., Minassian, N. A., Stevanin, G., Figueroa, K. P., Bannister, J. P. A., Nolte, D., Mock, A. F., Evidente, V. G. H., Fee, D. B., Müller, U., et al. (2006) · Nature Genetics · doi:10.1038/ng1758 · Cited by 313
Inflammasome-mediated innate immunity in Alzheimer’s disease
Venegas, C., & Heneka, M. T. (2019) · The FASEB Journal · doi:10.1096/fj.201900439 · Cited by 93
“4, inhippocampalneurons (44)aswell as in early stages of AD and in transgenic mice (45).”
Background
Metadata
- Authors
- Angulo, E., Noé, V., Casadó, V., Mallol, J., Gomez‐Isla, T., Lluis, C., Ferrer, I., Ciudad, C. J., & Franco, R.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2004-10
- Volume
- 91
- Issue
- 3
- Pages
- 547-557
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2048751652
- Cited by
- 84
- References
- 10
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Up‐regulation of the Kv3.4 potassium channel subunit in early stages of Alzheimer's disease. https://app.cochat.ai/papers/10.1111/j.1471-4159.2004.02771.x
- The paper
- Angulo, E., Noé, V., Casadó, V., Mallol, J., Gomez‐Isla, T., Lluis, C., Ferrer, I., Ciudad, C. J., & Franco, R. (2004). Up‐regulation of the Kv3.4 potassium channel subunit in early stages of Alzheimer's disease. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2004.02771.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.